• Clinical Evidence

Use of a Computer-Guided Glucose Management System to Improve Glycemic Control and Address National Quality Measures: A 7-Year, Retrospective Observational Study at a Tertiary Care Teaching Hospital

Setting: 900-bed tertiary care teaching hospital

Objectives

This retrospective observational study evaluates the impact of using a computer-guided glucose management system (EndoTool) for patients admitted to intensive care and intermediate units, with an analysis of data from a period of seven years, 16,850 visits and 492,078 blood glucose readings.

Setting

900-bed tertiary care teaching hospital.

Results

  • Average time to a target blood glucose <=180 mg/dL was between 1.5 and 2.3 hours.
  • Average rate of glucose excursions (defined as a blood glucose >180 mg/dL after control was achieved) was 4%, at an average duration of 1.91 hours.
  • Incidence of hypoglycemia <40 mg/dL was 0.03% of blood glucose readings.
  • Incidence of hypoglycemia <70 mg/dL was 0.93% of blood glucose readings, a rate that decreased 96% over the study period, from 1.04% to 0.046%, concurrent to a near-doubling of visits.
  • Among the subset of cardiovascular surgery patients, average time to a target blood glucose <140 mg/dL was between 4.5 and 4.8 hours and was achieved by ~98% of patients.
  • Rate of hospital-acquired conditions per 1,000 under HAC-8 (manifestations of poor glycemic control) decreased 61%, from 0.083 pre-EndoTool to 0.032 post-EndoTool, for a ranking in the top 10% of U.S. hospitals.

Conclusions

Use of a computer-guided glucose management system (EndoTool) leads to significant improvements in overall glucose control and quality of care, with relatively rapid time to target, low rate of glucose excursions, minimal hypoglycemia and a marked decrease in the rate of hospital-acquired conditions under HAC-8 (manifestations of poor glycemic control).
Objective

This retrospective observational study evaluates the impact of using a computer-guided glucose management system (EndoTool) for patients admitted to intensive care and intermediate units, with an analysis of data from a period of seven years, 16,850 visits and 492,078 blood glucose readings.

Setting

900-bed tertiary care teaching hospital.

Results
  • Average time to a target blood glucose <=180 mg/dL was between 1.5 and 2.3 hours.
  • Average rate of glucose excursions (defined as a blood glucose >180 mg/dL after control was achieved) was 4%, at an average duration of 1.91 hours.
  • Incidence of hypoglycemia <40 mg/dL was 0.03% of blood glucose readings.
  • Incidence of hypoglycemia <70 mg/dL was 0.93% of blood glucose readings, a rate that decreased 96% over the study period, from 1.04% to 0.046%, concurrent to a near-doubling of visits.
  • Among the subset of cardiovascular surgery patients, average time to a target blood glucose <140 mg/dL was between 4.5 and 4.8 hours and was achieved by ~98% of patients.
  • Rate of hospital-acquired conditions per 1,000 under HAC-8 (manifestations of poor glycemic control) decreased 61%, from 0.083 pre-EndoTool to 0.032 post-EndoTool, for a ranking in the top 10% of U.S. hospitals.
Conclusions

Use of a computer-guided glucose management system (EndoTool) leads to significant improvements in overall glucose control and quality of care, with relatively rapid time to target, low rate of glucose excursions, minimal hypoglycemia and a marked decrease in the rate of hospital-acquired conditions under HAC-8 (manifestations of poor glycemic control).

References

Authors

Robert Tanenberg, MD, FACP; Sandra Hardee, PharmD, CDE; Caitlin Rothermel, MA, MPH; Almond Drake 3rd, MD, FACE.

Source

Published in Endocrine Practice, Volume 23, Issue 3, p331-341.

Year

2017

Quick navigation
Objectives
Setting
Results
Conclusions
References
Objective

This retrospective observational study evaluates the impact of using a computer-guided glucose management system (EndoTool) for patients admitted to intensive care and intermediate units, with an analysis of data from a period of seven years, 16,850 visits and 492,078 blood glucose readings.

Setting

900-bed tertiary care teaching hospital.

Results
  • Average time to a target blood glucose <=180 mg/dL was between 1.5 and 2.3 hours.
  • Average rate of glucose excursions (defined as a blood glucose >180 mg/dL after control was achieved) was 4%, at an average duration of 1.91 hours.
  • Incidence of hypoglycemia <40 mg/dL was 0.03% of blood glucose readings.
  • Incidence of hypoglycemia <70 mg/dL was 0.93% of blood glucose readings, a rate that decreased 96% over the study period, from 1.04% to 0.046%, concurrent to a near-doubling of visits.
  • Among the subset of cardiovascular surgery patients, average time to a target blood glucose <140 mg/dL was between 4.5 and 4.8 hours and was achieved by ~98% of patients.
  • Rate of hospital-acquired conditions per 1,000 under HAC-8 (manifestations of poor glycemic control) decreased 61%, from 0.083 pre-EndoTool to 0.032 post-EndoTool, for a ranking in the top 10% of U.S. hospitals.
Conclusions

Use of a computer-guided glucose management system (EndoTool) leads to significant improvements in overall glucose control and quality of care, with relatively rapid time to target, low rate of glucose excursions, minimal hypoglycemia and a marked decrease in the rate of hospital-acquired conditions under HAC-8 (manifestations of poor glycemic control).

References

Authors

Robert Tanenberg, MD, FACP; Sandra Hardee, PharmD, CDE; Caitlin Rothermel, MA, MPH; Almond Drake 3rd, MD, FACE.

Source

Published in Endocrine Practice, Volume 23, Issue 3, p331-341.

Year

2017

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Temple Health, a 3-hospital academic system was experiencing high rates of hypoglycemia due to reliance on sliding scale insulin (SSI). To improve safety and align with ADA guidelines, the hospital implemented EndoTool SubQ, a patient-specific insulin dosing software the supports four dosing protocols, including basal-bolus-correction (BBC).
Image
  • Clinical Evidence

How Corewell Health Reduced LOS for DKA Patients, Slashing Costs by Almost $1M

How Corewell Health Reduced LOS for DKA Patients, Slashing Costs by Almost $1M

The objective of this study was to evaluate the impact of EndoTool IV insulin dosing software on mortality, length of stay, readmission rates, and cost of care for patients treated for Diabetic Ketoacidosis (DKA) at Corewell Health West.
Image
  • Clinical Evidence

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

The objective of this study was to evaluate the impact of renal insufficiency on hypoglycemia rates in patients treated for Diabetic Ketoacidosis (DKA) utilizing a computerized insulin dosing algorithm.
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.